HC Wainwright Reiterates Buy Rating on Biodesix, Inc. (BDSX)

On June 15, 2026, HC Wainwright analyst Yi Chen reiterated a buy rating on Biodesix, Inc. (NasdaqGM: BDSX), maintaining a price target of $26. Biodesix shares are currently trading around $15.06.

Other Institutional Activity in Biodesix

Several institutional investors have recently adjusted their positions in Biodesix. AIGH Capital Management LLC added 758,328 shares, bringing its total to 758,328 shares valued at approximately $11 million. Telemark Asset Management, LLC increased its holdings by 162,000 shares to a total of 489,824 shares worth about $7.1 million. Aberdeen Group PLC boosted its stake by 196,013 shares, ending with 458,438 shares valued at $6.6 million. Soleus Capital Management, L.P. added 416,599 shares, while Birchview Capital, LP maintained its position with 286,804 shares.

Biodesix, Inc. Stock Snapshot

Shares of Biodesix, Inc. (NasdaqGM: BDSX) are trading near $15.06. The company has a market cap of approximately $161.6 million. It is not currently profitable, with no meaningful forward P/E ratio. Biodesix has a beta of 0.593, indicating lower volatility compared to the market. The stock's 52-week range is between $5.00 and $20.21, with a 50-day moving average of $13.94 and a 200-day moving average of $10.70. The company has a current ratio of 2.82 and a quick ratio of 2.42, though its debt-to-equity ratio is notably high at 805.61.

Recent Earnings

Biodesix reported revenues of $96.1 million with a growth rate of 42.3%. However, the company posted a net margin of -33.3% and a return on equity of -316.5%, reflecting ongoing challenges in achieving profitability. Biodesix is expected to release its next earnings report on August 6, 2026.

Insider Buying and Selling at Biodesix, Inc.

Recent insider transactions at Biodesix include sales by CFO Robin Harper Cowie, Chief Accounting Officer Chris Vazquez, Chief Commercial Officer Kieran O'Kane, and President & CEO Scott Hutton, each selling shares at an average price of $12.78 on February 23, 2026. Additionally, insider John Patience made a small purchase on March 31, 2026.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright & Co. initiated coverage on Biodesix with a buy rating and a $26 price target. Canaccord Genuity has also maintained its buy rating with a $22 target as of May 5, 2026. The consensus among analysts is a buy rating, with an average price target of $30.50 based on four analyst opinions.

About Biodesix, Inc.

Biodesix, Inc., headquartered in Louisville, Colorado, is a healthcare company specializing in diagnostic solutions. It offers blood-based tests for lung cancer, including the Nodify Lung Nodule Risk Assessment and the IQLung testing strategy, which help in assessing cancer risk and guiding treatment decisions. The company also provides a range of diagnostic services for biopharmaceutical and life sciences companies and operates several laboratories. Biodesix is led by CEO Scott Hutton and employs around 334 people.

Bottom Line

HC Wainwright's reiterated buy rating on Biodesix reflects ongoing confidence in the company's potential, despite its current lack of profitability. Investors and analysts are closely monitoring Biodesix's progress as it continues to develop its diagnostic solutions. The information from analyst ratings and insider transactions offers valuable insights into market sentiment, but it's important to remember that these are historical observations and may not reflect the current state of the company.